Skip to main content

Table 1 Expression of various markers in PTs obtained from patients or patient-derived xenografts

From: Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells

 

% positive cases (n = 51)

BC007/BC-P007MT1

BC107/BC-P107MT1

BC515/BC-P515MT1

BC877/BC-P877MT1

HS-5

(% positive cells)

MSC marker

CD44

68.6%

50/60

60/30

-/-

-/-

+

CD29

27.4%

10/40

<5/30

5/<1

-/-

+

CD166

78.4%

<5/< 5

10/50

5/5

90/90

+

CDI06

29.4%

30/<10

<10/<10

-/-

80/80

+

CD105

1.9%

-/-

-/-

-/-

50/90

+

CD90

78.4%

<10/< 10

10/10

55/75

<5/70

+

CD117

70.5%

-/20

-/-

5/50

80/95

+

GD2

100%

80/50

75/30

90/75

60/30

+

(<10 to >90)

     

Stem cell marker

ALDH

100%

20/1

3-5/<1

40/5

<1/<5

+

(<10 to >90)

     

Oct-4

47.0%

10/5

30/10

<1/35

<5/<5

+

PT clinically relevant markers

Vimentin

100%

90/ > 90

90/>70

80/20

>95/>95

+

(<10- to >90)

     

Ki-67

82.3%

40/40

10/20

5/<3

65/>95

+

CD10

60.7%

20/5

10/70

5/5

<10/30

+

CD34

52.9%

-/-

40/70

80/20

-/-

-

p53

50.9%

<10/<10

<5/10

70/60

>95/>95

+

Bcl-2

37.2%

-/-

-/-

-/-

-/-

-

p63

9.8%

60/10

-/-

-/-

-/-

-

Globo-H

9.8%

-/-

-/-

-/-

80/80

-

  1. Fifty-one malignant PTs were tested by immunohistochemical staining for a panel of 18 markers. The expression level of each marker was scored based on the positive percentage by stained cells by clinical pathologists. The percentage of all 51 cases expressing each marker is listed in the third row. The xenografted tumors in NO-SCID mice (BC-P007MT1, BC-P107 MT1, BC-P515 MT1 and BC-P877 MT1) showed a similar immunohistochemical staining profile for most markers as did the parental tumors (BC007, BC107, BC515 and BC877). All markers were expressed in malignant PTs. HS-5 (human marrow stromal cell lines) as the control in this table, the expression level of each marker was classified into two categories, negative (-) and positive (+), by clinical pathologists.